Research analysts at Needham & Company began coverage on shares of Aastrom Biosciences (NASDAQ: ASTM) in a report released on Tuesday. The firm set a “buy” rating and a $5.00 price target on the stock.
Shares of Aastrom Biosciences traded up 0.95% during mid-day trading on Tuesday, hitting $2.13. Aastrom Biosciences has a 52 week low of $1.75 and a 52 week high of $3.47. The company’s market cap is $82.5 million.
Several other analysts have also recently commented on the stock. Analysts at Ascendiant Capital Markets initiated coverage on shares of Aastrom Biosciences in a research note to investors on Tuesday, May 15th. They set a “strong-buy” rating and a $4.25 price target on the stock. Separately, analysts at Oppenheimer (NYSE: OPY) reiterated a “market perform” rating on shares of Aastrom Biosciences in a research note to investors on Friday, May 11st. Finally, analysts at WBB Securities upgraded shares of Aastrom Biosciences from a “hold” rating to a “speculative buy” rating in a research note to investors on Monday, April 16th. They now have a $3.00 price target on the stock, up previously from $2.50.
Aastrom Biosciences, Inc. (Aastrom) is in the development-stage. Aastrom is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues.